Skip to main content
placeholder image

Ant/psychotic and mood stabiliser prescription trends in Australia: research in Progress

Conference Paper


Abstract


  • Objectlves:Background and aims:

    This study investigates the prescription of the primary pharmaceutical treatments for serious mental illness namely;

    antipsychotics and mood stabilisers. Prescribing rates of both classes will be investigated separately. Specifically;

    typical and atypical antipsycholics will be investigated in context of the CATIE and CUtLASS studies to elucidate the

    impact of these pivotal studies upon prescription rates. In regards to mood stabilisers the prescription of lithium and

    sodium valproate will be compared; to establish if Australia is following a similar trend to the reduction in lithium

    prescribing apparent internationally.

    Materials and methods:

    Data from the Australian Pharmaceutical Benefits Scheme (PBS) will be audited to obtain total number of

    prescriptions. This will firstly be performed for each pharmaceutical drug class (i.e. atypical, typical, mood-stabiliser

    [lithium+ sodium valproate]). Secondly, this data will be recorded for each individual drug from each class (E.g. each

    typical anti psychotic etc.) The resultant data set pertaining to each year of interest (See Table 1) will be taken in

    context with Historical Australian population figures. Results:

    This research is currently in progress and the results pertaining to both antipsychotics and mood stabilisers will be

    presented.

    Conclusions:

    This study is the first national analysis to utilise both historical and contemporary population-longitudinal (PBS

    sourced) data to analyse national prescription trends in both antipsychotic and mood-stabilising medications Australia. The apparent trends In the prescription rates of both antipsychotlcs and mood stabilisers will be discussed. Recommendations will be made for further research.

UOW Authors


  •   Wells, S (external author)
  •   Mooyman, A (external author)
  •   Vella, Shae-Leigh (external author)
  •   Pai, Nagesh

Publication Date


  • 2018

Citation


  • Wells, S., Mooyman, A., Vella, S. L. & Pai, N. (2018). Ant/psychotic and mood stabiliser prescription trends in Australia: research in Progress. WPA thematic Congress Innovation in psychiatry: Effective interventions for health and Society (pp. 1-2).

Start Page


  • 1

End Page


  • 2

Abstract


  • Objectlves:Background and aims:

    This study investigates the prescription of the primary pharmaceutical treatments for serious mental illness namely;

    antipsychotics and mood stabilisers. Prescribing rates of both classes will be investigated separately. Specifically;

    typical and atypical antipsycholics will be investigated in context of the CATIE and CUtLASS studies to elucidate the

    impact of these pivotal studies upon prescription rates. In regards to mood stabilisers the prescription of lithium and

    sodium valproate will be compared; to establish if Australia is following a similar trend to the reduction in lithium

    prescribing apparent internationally.

    Materials and methods:

    Data from the Australian Pharmaceutical Benefits Scheme (PBS) will be audited to obtain total number of

    prescriptions. This will firstly be performed for each pharmaceutical drug class (i.e. atypical, typical, mood-stabiliser

    [lithium+ sodium valproate]). Secondly, this data will be recorded for each individual drug from each class (E.g. each

    typical anti psychotic etc.) The resultant data set pertaining to each year of interest (See Table 1) will be taken in

    context with Historical Australian population figures. Results:

    This research is currently in progress and the results pertaining to both antipsychotics and mood stabilisers will be

    presented.

    Conclusions:

    This study is the first national analysis to utilise both historical and contemporary population-longitudinal (PBS

    sourced) data to analyse national prescription trends in both antipsychotic and mood-stabilising medications Australia. The apparent trends In the prescription rates of both antipsychotlcs and mood stabilisers will be discussed. Recommendations will be made for further research.

UOW Authors


  •   Wells, S (external author)
  •   Mooyman, A (external author)
  •   Vella, Shae-Leigh (external author)
  •   Pai, Nagesh

Publication Date


  • 2018

Citation


  • Wells, S., Mooyman, A., Vella, S. L. & Pai, N. (2018). Ant/psychotic and mood stabiliser prescription trends in Australia: research in Progress. WPA thematic Congress Innovation in psychiatry: Effective interventions for health and Society (pp. 1-2).

Start Page


  • 1

End Page


  • 2